Anhui Anke

Anhui Anke Biotechnology (Group) Co., Ltd., commonly known as Anke Bio, is a leading Chinese biopharmaceutical company specializing in the research, development, and manufacturing of recombinant DNA products. Founded in 1993 and headquartered in Hefei, the company has established a dominant market position with its flagship products, Ansomone (recombinant human growth hormone) and Anferon (recombinant human interferon alpha-2b). Anke Bio's business spans biopharmaceuticals, diagnostic reagents, and precision medicine, with a growing focus on oncology and cell therapy. The company is publicly listed on the Shenzhen Stock Exchange and is recognized as a key high-tech enterprise in China's 863 program. Through its various subsidiaries, Anke Bio is advancing a diverse pipeline that includes long-acting hormones, biosimilars, and innovative CAR-T cell therapies.